J Korean Med Assoc.  2011 Sep;54(9):953-956. 10.5124/jkma.2011.54.9.953.

Therapy for idiopathic precocious puberty in children

• Shim KS
• Kim JT

• KMID: 2191180
• DOI: http://doi.org/10.5124/jkma.2011.54.9.953

Abstract

The incidence of idiopathic precocious puberty is rapidly increasing in Korea. The most common medication used for treatment is a gonadotropin releasing hormone agonist. However, there is some debate regarding the indication and timing of treatment, and the dosage of the medication, because there are many factors that can affect growth in children after delaying puberty. Also, there are new medications that can potentially delay the puberty with children, for example, gonadotropin releasing hormone antagonists and aromatase inhibitors which require extensive further study.

Keyword

Precocious puberty; Gonadotropin-releasing hormone; Agonist

MeSH Terms

Aromatase Inhibitors
Child
Gonadotropin-Releasing Hormone
Humans
Incidence
Korea
Puberty
Puberty, Precocious
Aromatase Inhibitors
Gonadotropin-Releasing Hormone

Figure

• 

  Figure 1 The total number and medical cost of patients with precocious puberty from 2006 through 2010 in Korea (From The early detection of precocious puberty [Internet]. Seoul: Health Insurance Review & Assessment Service; 2011) [3].

Reference

1. Rosenfield RL, Cooke DW, Radovick S. Sperling MA, editor. Puberty and its disorders in the female. Pediatric endocrinology. 2008. 3rd ed. Philadelphia: Saunders Co;530–609.

2. Styne D, Grumbach M. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Puberty: ontogeny, neuroendocri-nology, physiology, and disorders. Williams textbook of endocrinology. 2008. 11th ed. Philadelphia: Saunders Co;969–1166.

3. The early detection of precocious puberty [Internet]. 2011. cited 2011 Aug 10. Seoul: Health Insurance Review & Assessment Service;Available from: http://www.hira.or.kr/cms/rc/rce_news/1205871_10816.html.

4. Shim KS, Bae CW, Yang YJ. A comparative study of the pu-berty suppression effect of gonadotropin-releasing hormone agonist in precocious or early puberty girls. Korean J Pediatr. 2008. 51:634–639.

5. Jin HY, Choi JH, Yoo HW. Evaluation of efficacy of GnRH agonist on predicted adult height (PAH) in patients with central precocious puberty using two different dosages. J Korean Soc Pediatr Endocrinol. 2010. 15:120–125.